drugset / Trial / NCT00557440

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

NCT00557440

Phase 2 Completed 37 enrolled Novartis
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.

Timeline

Start
2007-11
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 250 ug Inhaled
Subject Indacaterol Other / unclassified 500 ug Inhaled
Subject Mometasone Other / unclassified 400 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications